You have free access to this content

Cancer

Cover image for Cancer

1 October 2008

Volume 113, Issue 7

Pages 1497–1716

  1. News

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. You have free access to this content
      CancerScope (pages 1497–1499)

      Carrie Printz

      Version of Record online: 17 SEP 2008 | DOI: 10.1002/cncr.23936

  2. Editorial

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. You have free access to this content
      Targeting prostate cancer for focal destruction : Can we find it? (pages 1500–1501)

      Samir S. Taneja and Basir Tareen

      Version of Record online: 22 AUG 2008 | DOI: 10.1002/cncr.23780

      With an increasing number of men diagnosed with low-risk prostate cancer because of prostate-specific antigen screening, there is growing focus on avoiding overtreatment by radical surgery or radiation. While focal destruction of prostate cancer is an appealing concept, it remains unclear whether current diagnostic tools provide an adequate ability to map cancer for focal destruction. Candidate selection and improvements in diagnostic tools are essential prior to implemention of focal therapy.

  3. Review Article

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. You have free access to this content
      Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics : To test or not to test, that is the question (pages 1502–1510)

      John F. Deeken, Rebecca Slack and John L. Marshall

      Version of Record online: 20 AUG 2008 | DOI: 10.1002/cncr.23777

      • original image

      Genetic screening, as currently available, does not provide a complete estimate of risk in patients to be treated with irinotecan, and evidence-based guidelines are lacking on the best actions to take even if test results are known. Although pharmacogenomic testing provides supplementary information, clinical judgment remains paramount.

  4. Original Articles

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Clinicopathologic characteristics of invasive lobular carcinoma of the breast : Results of an Analysis of 530 Cases From a Single Institution (pages 1511–1520)

      Enrico Orvieto, Eugenio Maiorano, Luca Bottiglieri, Patrick Maisonneuve, Nicole Rotmensz, Viviana Galimberti, Alberto Luini, Fabricio Brenelli, Giovanna Gatti and Giuseppe Viale

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23811

      • original image

      Invasive lobular carcinoma (ILC) can be subdivided into classic (57%) and nonclassic types (43%). Histopathologic subtyping of these tumors, in addition to traditional clinicopathologic features, is a prognostic parameter that indicates a more favorable outcome for the classic type of ILC.

    2. You have free access to this content
      Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer (pages 1521–1526)

      Amanda I. Phipps, Kathleen E. Malone, Peggy L. Porter, Janet R. Daling and Christopher I. Li

      Version of Record online: 25 AUG 2008 | DOI: 10.1002/cncr.23786

      In this population-based, case–control study, associations between reproductive factors and breast cancer risk were estimated for subtypes of breast cancer distinguished by estrogen receptor (ER), progesterone receptor (PR), and HER-2 status. Prolonged breastfeeding was found to be associated with a significantly reduced risk of both luminal (ER–positive) and triple-negative (ER-negative [-]/PR-/HER-2-) breast cancers, and heterogeneity between subtype-specific associations was pronounced for many risk factors.

    3. Endocrine Disease
      You have free access to this content
      Sentinel lymph node biopsy as guidance for central neck dissection in patients with papillary thyroid carcinoma (pages 1527–1531)

      Jong-Lyel Roh and Chan II Park

      Version of Record online: 31 JUL 2008 | DOI: 10.1002/cncr.23779

      • original image

      Sentinel lymph node (SLN) biopsy was performed in 50 patients who had papillary thyroid carcinoma with no suspicious lymph nodes. Biopsy identified SLN in 46 patients (92%) and detected metastatic lymph nodes in 14 of 18 patients (78%). Intraoperative SLN biopsy was found to be a safe and feasible method for highly accurate detection of central lymph node metastases.

  5. Review Article

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. You have free access to this content
      Genetic aberrations of gastrointestinal stromal tumors (pages 1532–1543)

      Jilong Yang, Xiaoling Du, Alexander J. F. Lazar, Raphael Pollock, Kelly Hunt, Kexin Chen, Xishan Hao, Jonathan Trent and Wei Zhang

      Version of Record online: 31 JUL 2008 | DOI: 10.1002/cncr.23778

      Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm in the gastrointestinal tract and is associated with mutations of the KIT or PDGFRA gene. Other genetic abnormalities were also found to contribute to the pathobiology of GISTs.

  6. Original Articles

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. Disease Site

      Genitourinary Disease
      You have free access to this content
      Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥50 ng/mL (pages 1544–1551)

      Brant A. Inman, Judson D. Davies, Laureano J. Rangel, Eric J. Bergstralh, Eugene D. Kwon, Michael L. Blute, R. Jeffrey Karnes and Bradley C. Leibovich

      Version of Record online: 4 AUG 2008 | DOI: 10.1002/cncr.23767

      • original image
      • original image
      • original image
      • original image

      Patients with prostate cancer and a serum prostate-specific antigen level ≥50 ng/mL have very high-risk prostate cancer that carries a high likelihood of being pathologically advanced. Although the probability of realizing long-term survival in these high-risk patients is less than in patients with more favorable disease, 10-year survival outcomes remain excellent and argue for aggressive management of these cases.

    2. You have free access to this content
      Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (pages 1552–1558)

      Robert J. Motzer, Ronald M. Bukowski, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sindy T. Kim, Charles M. Baum and Michael W. Kattan

      Version of Record online: 20 AUG 2008 | DOI: 10.1002/cncr.23776

      • original image
      • original image
      • original image
      • original image

      In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC) with clear-cell histology. By analyzing the 375 patients who received sunitinib in this trial, a nomogram was developed from pretreatment clinical features to predict the probability of achieving 12-month progression-free survival with sunitinib therapy for metastatic RCC.

    3. You have free access to this content
      Utility of extended pattern prostate biopsies for tumor localization : Pathologic correlations after radical prostatectomy (pages 1559–1565)

      Ryan T. Schulte, David P. Wood, Stephanie Daignault, Rajal B. Shah and John T. Wei

      Version of Record online: 22 AUG 2008 | DOI: 10.1002/cncr.23781

      • original image

      Positive predictive values of right and left needle biopsy were high at 97.3% and 96.7%; however, the negative predictive values were low at 24.7% and 31.3%. Contemporary extended pattern prostate biopsies, although able to diagnose cancers, fail to provide reliable localization of tumors to specific areas of the prostate.

    4. Head and Neck Disease
      You have free access to this content
      Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma (pages 1566–1571)

      Carmen J. Marsit, Marshall R. Posner, Michal D. McClean and Karl T. Kelsey

      Version of Record online: 18 AUG 2008 | DOI: 10.1002/cncr.23770

      • original image

      The authors examined the etiology of and prognostic potential of E-cadherin (ECAD) methylation in population-based case series of patients with head and neck squamous cell carcinoma. The results indicated that ECAD methylation occurs more often in low smokers or never smokers and that it is a marker of better overall patient survival.

    5. You have free access to this content
      The prognostic role of comorbidity in salivary gland carcinoma (pages 1572–1579)

      Chris H. J. Terhaard, Marc P. van der Schroeff, Kim van Schie, Simone E. J. Eerenstein, Herman Lubsen, Johannes H. A. M. Kaanders, Ludwig E. Smeele, Fred R. Burlage, Piet L. van Den Ende and Robert J. Baatenburg de Jong

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23771

      • original image
      • original image
      • original image
      • original image

      The authors investigated the prevalence and relevance of prognostic comorbidity grade according to the Adult Comorbidity Evaluation-27 comorbidity index in patients with salivary gland cancer. Compared with other studies that investigated the effects of comorbidity on patients with head and neck cancer, the current results indicated that patients with salivary gland cancer have less comorbidity and that their comorbidity status is comparable to that among patients with other nonsmoking- and nonalcohol-related cancers.

    6. Hematologic Malignancies
      You have free access to this content
      Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation (pages 1580–1587)

      Michael Choi, Can-Lan Sun, Seira Kurian, Andrea Carter, Liton Francisco, Stephen J Forman and Smita Bhatia

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23773

      • original image
      • original image

      In this study, the authors identified a subpopulation of patients who underwent hematopoietic cell transplantation and were at increased risk for chronic kidney disease. These findings set the stage for appropriate long-term follow-up of vulnerable patients.

    7. You have free access to this content
      A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (pages 1588–1595)

      Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Velia Bongarzoni, Alessandro Andriani, Giovanni D'Arena, Enrico Balleari, Giuseppe Pietrantuono, Mario Boccadoro and Antonio Palumbo

      Version of Record online: 5 AUG 2008 | DOI: 10.1002/cncr.23783

      • original image
      • original image

      A randomized clinical trial comparing 1-year administration of zoledronic acid versus simple observation was conducted in 163 patients with asymptomatic myeloma. The results of this study indicate that the use of zoledronic acid in these patients reduces the development of skeletal events at the time of disease progression but does not influence the rate of or time to transformation into symptomatic myeloma.

    8. You have free access to this content
      Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia (pages 1596–1604)

      Azra Raza, Murtaza Mehdi, Muhammad Mumtaz, Fahad Ali, Steven Lascher and Naomi Galili

      Version of Record online: 20 AUG 2008 | DOI: 10.1002/cncr.23789

      • original image
      • original image

      New therapies are needed for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) despite recent advances. In this study, low-dose 5-azacytidine combined with thalidomide was found to be well-tolerated and was highly effective for the treatment of patients with MDS and AML arising from prior MDS.

    9. You have free access to this content
      The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes (pages 1605–1613)

      Apostolia Maria Tsimberidou, Elihu Estey, Sijin Wen, Sherry Pierce, Hagop Kantarjian, Maher Albitar and Razelle Kurzrock

      Version of Record online: 5 AUG 2008 | DOI: 10.1002/cncr.23785

      • original image

      Serum levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1 receptor antagonist, IL-6, IL-10, and endostatin were measured in patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. TNF-α levels <10 pg/mL were associated with higher rates of complete remission (P = .003), survival (P = .0003), and event-free survival (P = .0009), but the other cytokines were not predictive of clinical outcomes.

    10. Hepatobiliary Disease
      You have free access to this content
      Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma : Clinical efficacy and factors influencing outcomes (pages 1614–1622)

      Jin Hyoung Kim, Hyun-Ki Yoon, Kyu-Bo Sung, Gi-Young Ko, Dong Il Gwon, Ji Hoon Shin and Ho-Young Song

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23787

      • original image
      • original image
      • original image

      Hepatic intra-arterial chemotherapy is well tolerated and may be effective at prolonging survival of patients with unresectable intrahepatic cholangiocarcinoma. Tumor vascularity is significantly associated with radiographic response. From the results of the current study, we can predict that patients with small or intermediate (<8 cm) tumor size, hypervascular tumors on angiography, and Child-Pugh class A, transcatheter arterial chemoembolization may be of benefit for treating cholangiocarcinoma.

    11. Lung Disease
      You have free access to this content
      Randomized phase 2 study of subcutaneous amifostine versus epoetin-α given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer (pages 1623–1631)

      Hye-Suk Han, Ji-Youn Han, Sun Young Yu, Hong Ryull Pyo, Hyae Young Kim, Kwan Ho Cho, Dae Ho Lee, Heung Tae Kim and Jin Soo Lee

      Version of Record online: 31 JUL 2008 | DOI: 10.1002/cncr.23790

      • original image
      • original image
      • original image

      The role of amifostine and epoetin-α to reduce severe toxicities during concurrent chemo-hyperfractionated radiotherapy (CCRT) was investigated for limited-disease small cell lung cancer (LD-SCLC). A total of 76 chemotherapy-naive patients with LD-SCLC were randomly assigned at registration to either amifostine or epoetin-α. Although amifostine during CCRT did not significantly reduce severe toxicities, epoetin-α was found to be effective in preventing severe anemia during CCRT in patients with LD-SCLC. Other radioprotectvie strategies to minimize severe toxicities should be investigated.

    12. Melanoma
      You have free access to this content
      A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma (pages 1632–1640)

      Ahmad A. Tarhini, John M. Kirkwood, William E. Gooding, Stergios Moschos and Sanjiv S. Agarwala

      Version of Record online: 21 AUG 2008 | DOI: 10.1002/cncr.23791

      • original image
      • original image

      In a phase 2 study, the authors tested a new approach of single-agent chemotherapy with temozolomide administered in an extended schedule followed by high-dose interleukin 2 (HD IL-2) to evaluate its safety and efficacy in patients with advanced metastatic melanoma. Although the sequential combination was safe and had lower toxicity than previously used biochemotherapy regimens, the overall response rate and the number of durable responses induced by this combination did not exceed the results obtained with single-agent HD IL-2.

    13. Neuro-Oncology
      You have free access to this content
      Brain metastasis from renal cell carcinoma : Presentation, recurrence, and survival (pages 1641–1648)

      Brian Shuch, Jeff C. La Rochelle, Tobias Klatte, Stephen B. Riggs, Weiqing Liu, Fairooz F. Kabbinavar, Allan J. Pantuck and Arie S. Belldegrun

      Version of Record online: 31 JUL 2008 | DOI: 10.1002/cncr.23769

      • original image
      • original image
      • original image
      • original image

      Patients with renal cell carcinoma brain metastases are frequently excluded from trials and to the authors' knowledge no guidelines currently exist regarding central nervous system surveillance or treatment. The objective of the current study was to assist in the creation of guidelines.

    14. Sarcoma
      You have free access to this content
      Liposarcoma : Outcome based on the Scandinavian Sarcoma Group register (pages 1649–1656)

      Katarina Engström, Peter Bergh, Pelle Gustafson, Ragnar Hultborn, Helena Johansson, Rickard Löfvenberg, Olga Zaikova, Clement Trovik, Ola Wahlström and Henrik C.F. Bauer

      Version of Record online: 20 AUG 2008 | DOI: 10.1002/cncr.23784

      • original image
      • original image
      • original image

      Well-differentiated liposarcomas rarely recur, despite intralesional or marginal surgical margins and lack of treatment with postoperative radiotherapy. According to Scandinavian Sarcoma Group guidelines, postoperative radiotherapy for high-grade liposarcomas with nonwide surgery was recommended, but compliance in this study was poor and local recurrence rate without radiotherapy was high.

    15. You have free access to this content
      The prognostic impact of dedifferentiation in retroperitoneal liposarcoma : A series of surgically treated patients at a single institution (pages 1657–1665)

      Chiara Mussi, Paola Collini, Rosalba Miceli, Marta Barisella, Luigi Mariani, Marco Fiore, Paolo G. Casali and Alessandro Gronchi

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23774

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      A series of patients with well differentiated or dedifferentiated (DD) retroperitoneal liposarcoma (RLS) was studied to evaluate the prognostic value of the presence, extension, and grade of the DD component. The results indicated that the presence of a DD component was the main independent prognostic factor both for local recurrence and survival in patients with RLS, whereas no difference was observed with regard to the rate of metastasis.

    16. Discipline

      Clinical Trials
      You have free access to this content
      Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 (pages 1666–1675)

      Jarrod P. Holmes, Jeremy D. Gates, Linda C. Benavides, Matthew T. Hueman, Mark G. Carmichael, Ritesh Patil, Dianna Craig, Elizabeth A. Mittendorf, Alexander Stojadinovic, Sathibalan Ponniah and George E. Peoples

      Version of Record online: 25 AUG 2008 | DOI: 10.1002/cncr.23772

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage–colony-stimulating factor in disease-free lymph node-positive and lymph node-negative breast cancer patients. Compared with suboptimally dosed patients, the optimally dosed E75 vaccine in disease-free breast cancer patients had similar toxicity but enhanced HER-2/neu-specific immunity that may lead to decreased recurrences with additional follow-up.

    17. Epidemiology
      You have free access to this content
      Incense use and respiratory tract carcinomas : A prospective cohort study (pages 1676–1684)

      Jeppe T. Friborg, Jian-Min Yuan, Renwei Wang, Woon-Puay Koh, Hin-Peng Lee and Mimi C. Yu

      Version of Record online: 25 AUG 2008 | DOI: 10.1002/cncr.23788

      The relation between incense use and the risk of carcinoma of the respiratory tract was investigated in a prospective cohort of 61,320 Singapore Chinese. Long-term use of incense was associated with an increased risk of squamous cell carcinoma of the respiratory tract.

    18. Symptom Control and Palliative Care
      You have free access to this content
      Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer : A systematic review (pages 1685–1694)

      Elie A. Akl, Sandeep Rohilla, Maddalena Barba, Francesca Sperati, Irene Terrenato, Paola Muti, Fadi Bdair and Holger J. Schünemann

      Version of Record online: 20 AUG 2008 | DOI: 10.1002/cncr.23814

      • original image
      • original image
      • original image
      • original image
      • original image

      Low-molecular-weight heparin most likely is superior to unfractionated heparin in reducing mortality in the initial treatment of venous thromboembolism in patients with cancer. The current study indicated that there is a need for more and better designed trials to confirm these findings.

    19. You have free access to this content
      Lipolysis—Not inflammation, cell death, or lipogenesis—Is involved in adipose tissue loss in cancer cachexia (pages 1695–1704)

      Mikael Rydén, Thorhallur Agustsson, Jurga Laurencikiene, Tom Britton, Eva Sjölin, Bengt Isaksson, Johan Permert and Peter Arner

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23802

      • original image
      • original image
      • original image
      • original image
      • original image

      The exact mechanisms underlying the loss of fat mass in cancer cachexia are not known. In this report, the authors provided evidence that increased lipolysis, not reduced lipogenesis or increased adipocyte cell death and inflammation, was the primary factor for adipose tissue loss in gastrointestinal cancer, thereby constituting a possible future therapeutic target.

    20. Translational Research
      You have free access to this content
      A multidisciplinary approach to honest broker services for tissue banks and clinical data : A pragmatic and practical model (pages 1705–1715)

      Rajiv Dhir, Ashok A. Patel, Sharon Winters, Michelle Bisceglia, Dennis Swanson, Roger Aamodt and Michael J. Becich

      Version of Record online: 5 AUG 2008 | DOI: 10.1002/cncr.23768

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Data annotation is a critical need for translational research projects. In this report, the authors describe an institutional review board-approved, Health Insurance Portability and Accountability Act-compliant model honest broker system that encompassed multiple data sources in a large tertiary healthcare system.

  7. Erratum

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    6. Review Article
    7. Original Articles
    8. Erratum
    1. You have free access to this content
      Erratum (page 1716)

      Version of Record online: 14 AUG 2008 | DOI: 10.1002/cncr.23877

SEARCH

SEARCH BY CITATION